Benta Strengthens Its European Presence with the Acquisition of the Italian CDMO NerPharMa in Milan
Milan, Italy, 18 February 2026 Benta has announced the acquisition of NerPharMa, a pharmaceutical manufacturing company located in Milan, Italy, from NMS Group. The acquisition marks a significant step in strengthening Benta’s European industrial platform and expanding its specialized oncology, biologics and high potency manufacturing capabilities.
Strategically located in one of Europe’s leading pharmaceutical hubs, NerPharMa operates a facility accredited by multiple regulatory authorities, including the EMA and the US FDA, and employs over 100 staff members. The site provides comprehensive manufacturing capabilities across biologics and high-potency integrated drug product (DP), as well as drug substance (DS) services in oral solid dosages and injectables. NerPharMa supports a diverse portfolio of active clients, ranging from local businesses to multinational corporations.
“This acquisition represents a significant step forward in expanding Benta’s European operations. It will enable us to enhance our capabilities in complex therapies, such as biologics and high-potency products, while strengthening our international client network. Benta is now positioning well as one stop shop CMO partner in all galenic forms from process chemistry to distribution,” said Bernard Tannoury, Chairman & CEO of Benta Group.
“This divestment marks a pivotal development in our transition towards becoming an organization dedicated to oncology innovation,” stated Dr. Hugues Dolgos, PharmD, CEO of NMS Group. “By focusing our efforts on small molecule and ADCs research and development, we are better positioned to expedite the advancement of the delivery of breakthrough treatments. I am confident that NerPharMa will continue to progress as part of Benta’s global network.”
Company Profiles
About Benta. Benta is an international healthcare group delivering integrated pharmaceutical manufacturing, CDMO services, and strategic healthcare solutions across global markets. Leveraging strong industrial platforms in Europe and the Middle East, Benta combines industrial excellence, regulatory expertise, and long-term partnerships to support innovation from early development through commercial manufacturing and patient access, while adhering to the highest standards of quality, compliance, and operational performance.
About NerPharMa NerPharMa is an Italian-based Contract Development and Manufacturing Organization (CDMO) specializing in the formulation and production of active pharmaceutical ingredients (APIs) and finished dosage forms. Known for its expertise in handling high-potency compounds and complex manufacturing requirements, NerPharMa provides integrated services from clinical-stage development to full-scale commercial production.
About NMS Group. NMS Group is an oncology focused company dedicated to the discovery and development of innovative cancer therapies. Based in Milan, Italy, the Group leverages its proprietary platforms to advance a pipeline of small molecule inhibitors and next-generation Antibody-Drug Conjugates (ADCs), aiming to address high unmet medical needs in global oncology.
Access the full press release here: